Long term outcomes in Finland

In Finland, all children with severe haemophilia are treated according to a single protocol, whether it’s delivered as part of comprehensive care or in a t...

Factor storage affects patients satisfaction

Clinicians should remind patients that clotting factors don’t generally need to be stored in the fridge because, a study from Italy suggests, this may infl...

Novel biotechnology gains special EU status

A technology that could offer people with haemophilia B an implant providing long term Factor IX synthesis has been awarded Advanced Therapy Medicinal Prod...

New evidence of the impact of haemophilia on individuals and carers

Two new reports have confirmed how common pain and psychiatric morbidity are among people with haemophilia. B-HERO-S is a US study of 299 adults with h...

New human fibrinogen concentrate available

FibCLOT, a new human fibrinogen concentrate is now available in the UK, offering increased therapeutic choices for patients affected by congenital fibrino...

Emicizumab meets study endpoint

22 December 2016 Prophylaxis with emicizumab reduced the number of bleeds over time compared with no prophylaxis in the HAVEN 1 study, which recruited ...

Elocta and Alprolix gain NHS reimbursement across the UK

21 September 2016 NHS England has confirmed reimbursement of Elocta® (efmoroctocog alfa) and Alprolix® (efrenonocog alfa) for the treatment of haemophilia ...

Emicizumab data looks encouraging

29 July 2016 Emicizumab, the humanized bispecific monoclonal antibody, in development by Roche/Genentech, continues to look promising for people with s...

EMA discounts increased inhibitor risk with Kogenate and Helixate

13 May 2016 Currently available evidence does not confirm that Kogenate Bayer/Helixate NexGen is associated with an increased risk of factor VIII inhib...

First longer-acting FVIII moves a step closer

28 September 2015 The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the ma...Once approved, Elocta will likely be the first prolonged half-life treatment option available for people with haemophilia A in the UK and Ireland.

EMA validates Alprolix (rFIXFc) marketing authorisation application

26 June 2015 The European Medicines Agency (EMA) has accepted Swedish Orphan Biovitrum AB (Sobi) and Biogen’s Marketing Authorisation Application for Alproli...

Sobi launches movie-maker app

Children living with haemophilia sometimes have a hard time talking about their condition or describing the implications the disease has on their life. Sob...

Bayer recruits children to long-acting trial

Bayer HealthCare has started to enroll children in an international phase III trial to evaluate its investigational compound BAY 94-9027 for the treatment ...

Another one bites the dust

Bad news for Bayer this week. The company has just announced the discontinuation of a Phase II/III trial evaluating the efficacy and safety of BAY 86-6150 ...

Baxter to Initiate Late-Stage Trial of Longer Acting Advate

Baxter in the US has submitted an Investigational New Drug (IND) application for its investigational haemophilia A treatment BAX 855 with the US Food and D...

B-LONG results positive for Biogen/SOBI

Wednesday 26 September 2013: Top-line results from the late-stage B-LONG trial suggest that Biogen/SOBIs’ long-lasting recombinant Factor IX Fc fusion prot...

New kid on the block looks promising

Pro Bono Bio Group plc has successfully concluded its pre-clinical trials in haemophilia patients using the world's first long acting blood Factors VIIa, V...

EMA Calls for Further Research on Personalized Approaches to Treating Hemophilia

The European Medicines Agency (EMA) has released a new reflection paper on the risks of adverse immune system reactions in hemophilia patients treated with...

Children to be seen (and heard) at EMA paediatric committee

Scrip reports that the European Medicines Agency is planning to allow children to participate in its paediatrics committee (PDCO) meetings to get their fee...

Inspiration files new FIX in US

Inspiration Biopharmaceuticals has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of IB1001,...

First patient screened in CSL Behring global phase I/III study of recombinant single-chain factor VIII

CSL Behring has screened the first patient in its recombinant coagulation single-chain factor VIII (rFVIII) trial, part of the AFFINITY clinical trial prog...

Inspiration initiates second trial of porcine FVIII

Inspiration Biopharmaceuticals, Inc. has announced the initiation of patient enrolment in the second of two pivotal studies in its OBI-1 Accur8 clinical tr...

FEIBA prophylaxis tops on-demand treatment for joint bleeds

Prophylaxis with FEIBA (anti-inhibitor coagulant complex, AICC) significantly and safely decreased the frequency of joint and other bleeding events compare...

Prenatal test extends choice for pregnant women

Pregnant women who carry the haemophilia gene could benefit from a non-invasive prenatal diagnostic test that analyses fetal DNA circulating in the mother’...

Member Log in

Not a member? Register here


Thanks to our Partners

Haemophilia Nurses' Association

Haemnet is a nurse-led initiative endorsed by the Haemophilia Nurses Association and supported by Pfizer Ltd, Bayer, Baxter Healthcare Ltd, BPL, Biotest, Grifols, CSL Behring, Octapharma, SOBI, LFB and Novo Nordisk. Sponsors are not responsible for site content.

Find out more about becoming a Haemnet partner

  • Sobi
  • CSL Behring
  • Pfizer
  • Roche
  • Novo Nordisk
  • Shire
  • Bayer Healthcare
  • BPL
  • Grifols
  • Biotest
  • LFB
  • Octapharma
  • Ferndale